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Sustained remission from depressive-like behavior
depends on hippocampal neurogenesis
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Impairment of hippocampal neurogenesis has been associated with the expression of depressive-like symptoms and some
studies have suggested neurogenesis as a critical factor in the normalization of behavior by antidepressant (AD) drugs. This
study provides robust evidence that ongoing neurogenesis is essential for the maintenance of behavioral homeostasis and that
its pharmacological arrest precipitates symptoms commonly found in depressed patients. Further, the incorporation of newly
born neurons and astrocytes into the preexisting hippocampal neurocircuitry is shown to be necessary for the spontaneous
recovery from the adverse effects of stress and for long-term benefits of AD treatments.
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Introduction
Major depression is a highly prevalent disorder that imposes a
significant social burden. While the pathophysiology of the
disease is still poorly understood, growing evidence suggests
that impaired neuroplasticity may be a key underlying
mechanism. Surrogate markers of impaired neuroplasticity,
such as reduced neuroproliferation and impoverished den-
dritic arborization in the hippocampus, have been implicated
in the onset, progression and remission of depressive
symptoms.1–4 Several antidepressants (ADs) tested to date
stimulate hippocampal neurogenesis,5–7 but it is unclear as to
whether these pro-neurogenic effects are responsible for their
mood-, emotional- and cognitive-improving actions. Recent
studies indicate that ADs exert their short-term therapeutic
effects by inducing remodeling of dendrites and synapses in
mood-regulating limbic brain regions rather than by stimulat-
ing neurogenesis per se;8–11 however, considering the long-
itudinal course of depression, the debate on whether the long-
term benefits of AD treatments result from altered hippocam-
pal neurogenesis and gliogenesis remains open.
In this study, we examined whether and how the neurogenic
process, from cell birth to integration of newly born cells into
the existing circuitry, influences the development of and
remission from depressive-like symptoms. Astrogliogenesis
was included in the present analysis in light of evidence that
astroyctes have a role in preventing of the expression of
depression-like behaviors in laboratory animals.12–14 A vali-
dated unpredictable chronic mild stress (uCMS) paradigmwas
implemented to induce core symptoms of depressive-like
behavior in rats; during the last 2 weeks of the uCMS protocol,
animals were administered imipramine or fluoxetine. To
assess the role of hippocampal neurogenesis and gliogenesis
in the long-term effects of ADs, cell proliferation was artificially
blocked through the coadministration of methylazoxymethanol
(MAM) with the ADs. After 1 month of recovery from the
experimental procedures, the behavioral dimensions com-
monly affected on depression were assessed and correlated
with hippocampal neuroplastic alterations.
Materials and methods
Animals and treatments. Male Wistar rats (200–250 g,
aged 2 months; Charles-River Laboratories, Barcelona,
Spain) were maintained under standard laboratory conditions
(12 h light: 12 h dark cycles, 22 1C, relative humidity of 55%,
ad libitum access to food and water). Groups of rats (n¼ 10–
12 per group) were randomly assigned to the following eight
experimental groups: non-stress controlþ saline or MAM;
stress (uCMS)þ saline or MAM; uCMSþ fluoxetine or imipra-
mine alone, or coadministered with MAM. All procedures were
carried out in accordance with EU Directive 2010/63/EU and
NIH guidelines on animal care and experimentation.
A validated uCMS protocol was applied for 6 weeks as
previously described.8,15 The ADs fluoxetine (10mgkg 1;
Kemprotec, Middlesborough, UK) and imipramine
(10mgkg 1; Sigma-Aldrich, St Louis, MO, USA) were
administered intraperitoneally (1ml kg 1); MAM (7mgkg 1;
MRIGlobal Chemical Carcinogen Repository, Kansas City,
MO, USA) was administered subcutaneously (0.45ml kg 1).
All drugs were dissolved in dimethyl sulfoxide (5%) and saline
(0.9%) and administered daily, during the 2 last weeks of the
uCMS protocol. Pilot studies showed that MAM did not
adversely influence general health parameters, such as
locomotor activity (ambulation in an open field, swimming
speed in a water maze) and fur quality.8,16,17 Here, we found no
significant alterations induced by MAM in appetite drive
(Supplementary Figure S1), in swimming performance in the
water maze (Supplementary Figure S2), as well as in weight
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variation (Supplementary Figure S3). BrdU was injected
intraperitoneally (50mgkg 1) for 5 days at the cessation of
uCMS in order to evaluate neurogenesis by immunocytochem-
istry (see below).
Subsequently, animals were allowed to recover for 4 weeks
and behavioral analyses were carried out at weeks 11 and 12,
during the daily light phase (09:00–18:00 h).
Behavioral analysis
Sucrose consumption test. Anhedonia was assessed on a
weekly basis by the sucrose consumption test, throughout
the experimental procedures. Baseline sucrose preference
values were established during a 1-week habituation period
during which animals were presented with two pre-weighed
drinking fluid bottles, containing water or 1% (m/v) sucrose.
Before each recording of sucrose preference, rats were food-
and water-deprived for 20 h and exposed to the test drinking
solutions for 1 h. Sucrose preference was calculated as
described previously.8
Elevated-plus maze. Anxiety-like behavior was examined
through the elevated-plus maze (EPM) test, in a 5-min
session, as previously described.15 The percentage of time
spent in the open-arm was used as an index of anxiety-like
behavior and the number of entries in the closed-arms was
taken as an indicator for locomotor activity (Supplementary
Figure S4).
Novelty suppressed feeding test. Anxiety-like traits were
further assessed through the NSF paradigm. After a 18-h
period of food-deprivation, animals were placed in an open-
field arena, as previously described,8 where a single food
pellet was positioned in the center. After reaching the pellet,
animals were individually returned to their home cage, where
pre-weighted food was available, and were allowed to feed
during 10min. The latency to feed in the open-field arena
was used as an anxiety-like behavior measurement, whereas
the food consumption in the animal home cages provided a
measure of appetite drive. No differences were observed in
the appetite drive between the experimental groups that
could lead to a misinterpretation of the results
(Supplementary Figure S1).
Forced swimming test. Learned-helplessness was assessed
through the forced swimming test. Assays were conducted
24 h after a 5-min pretest session, by placing the rats in
transparent cylinders filled with water (25 1C; 50 cm of depth)
during 5min. Trials were video-recorded and the immobility
time, as well as the latency to immobility were measured
using an automated video tracking system (Viewpoint,
Champagne au mont d’or, France). Learned-helplessness
was considered as an increase in the immobility time.
Results were complemented with the analysis of latency to
immobility, as a second measure of learned-helplessness
(Supplementary Figure 5).
Cognitive assessment. Cognitive function was evaluated in
a spatial working memory task and in a behavioral flexibility
task, performed in a black circular tank (170 cm diameter)
filled with water (23 1C; 31 cm of depth) placed in dimly lit
room with extrinsic clues. The water tank was divided in four
quadrants by imaginary lines and a black platform (12 cm
diameter; 30 cm high), invisible to rodents, was placed in one
of the quadrants. Trials were video-captured by a video-
tracking system (Viewpoint). Animals were habituated to the
test room, during the 2 days preceding the tests, being kept
in the room for 1 h in each day. These tests were conducted
as it follows:
Working memory task
The working memory task was used to evaluate the cognitive
domain that relies on the interplay between the hippocampal
and prefrontal cortex functions.18 The goal of this task, a
modification of the original spatial reference memory test, is to
assess the ability of animals to learn the position of the hidden
platform and to retain this information during four consecutive
trials. An escape platform was placed in one of the quadrants,
and was maintained in the same position during the four daily
trials. The test was performed during four days, and in each day
the platform was repositioned in a new quadrant in a clockwise-
fashion. In each of the daily trials animals were positioned in
a different starting point (north, east, west and south) and a trial
was considered as concluded when the platform was reached
within the time-limit of 120s. If the animals were unable to
find the platform during the trial time they were guided to the
platform and allowed to stay in it for 30s. The time of escape
latency was recorded for each trial.
Behavioral flexibility task. Following working memory
assessment, tests were conducted for 4 days maintaining
the platform in the same quadrant. At the fifth day, the beha-
vioral flexibility performance of animals, a prefrontal cortex-
dependent function, was tested by positioning the platform in a
new (opposite) quadrant. Animals were tested in four trials
according to the same procedure previously described. Besides
the time of escape latency, the time spent in both new and
old quadrants were recorded. Analysis of memory acquisition in
the 4 days preceding was conducted in order to assess whether
the different animal groups had equivalent memory for the
old platform position (Supplementary Figure 6).
To confirm that differences observed in the escape latency
were not due to distinct locomotor performance, wemeasured
the average swimming velocities during trials. No differences
were found among the groups in this parameter (Supple-
mentary Figure S2).
Immunostaining procedures. Animals were deeply anaesthe-
tized with sodium pentobarbital (20%; Eutasil, Sanofi) and
were transcardially perfused with cold 4% paraformaldehyde.
Brains were removed and post-fixed in 4% paraformaldehyde.
Coronal cryosections (20 mm) and vibratome sections
(40mm) were firstly stained for BrdU (1:50; Dako, Glostrup,
Denmark), followed by staining for DCX (for neuroblasts,
1:500; Abcam, Cambridge, UK), NeuN (for mature neurons;
1:100; Chemicon, Temecula, CA, USA) or GFAP (for glia;
1:200; Dako). Finally, all sections were stained with 4’,6-
diamidino-2-phenylindole (1mgml 1). For each animal, BrdU-
positive cells within the subgranular zone of the dentate gyrus
were analyzed after double staining with neuronal (DCX or
NeuN) or glial (GFAP) markers and cell counts were
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performed by confocal microscopy (Olympus FluoViewTM
FV1000, Hamburg, Germany). Hippocampal proliferation at
the end of the recovery period was assessed by Ki67 staining
(1:200; Leica Microsystems, Wetzlar, Germany). Estimation
of cell density in the dentate gyrus was obtained by crossing
the cell number values with the corresponding dentate gyrus
areas, determined using a Olympus BX51 optical microscope
and the Newcast software (Visiopharm, Horsholm, Denmark).
Three-dimensional morphological analysis. To assess the
three-dimensional dendritic morphology of characterized
hippocampal neurons, we developed a new technique that
combines Golgi-Cox impregnation with immunofluorescence
staining. Briefly, brains were immersed in Golgi-Cox solution
for 21 days and then transferred to a 30% sucrose solution
and cut on a vibratome. Coronal sections (200 mm thick) were
collected in 6% sucrose and blotted dry onto gelatin-coated
microscope slides. They were subsequently alkalinized in
18.7% ammonia, developed in Dektol (Kodak, Rochester,
NY, USA), fixed in Kodak Rapid Fix, dehydrated and xylene
cleared. An adapted optimized BrdU immunostaining proce-
dure was then applied in order to identify newly born
neurons. Dendritic arborization, spine numbers and shape
were, therefore, analyzed specifically in newborn BrdUþ
cells and compared with non-BrdUþ neurons. The detailed
method has been described in detail elsewhere.19
Statistical analysis. Statistical analyses were done using
SPSS software (SPSS, Chicago, IL, USA). After confirmation
of homogeneity, data was subjected to appropriate statistical
tests. Analysis of variance repeated measures was used to
analyze cognitive-learning tasks performance. One-way ana-
lysis of variance was used to evaluate the remaining
behavioral and molecular results. F-values and P-values
derived from the between groups analysis of variance
analyses are properly indicated along the text. Differences
between the groups were determined by Bonferroni’s post-hoc
multiple comparison test, and the corresponding P-values are
indicated in the figures. A t-test was used two evaluate
differences among the two groups where appropriate.
Statistical significance was accepted for Po0.05.
Results
Blockage of hippocampal proliferation triggers depres-
sive-like symptomatology in naive rats. We first analyzed
the long-term behavioral effects of neuro- and gliogenesis
pharmacological suppression in naive animals (non-stressed
animals), 4 weeks after the cessation of MAM treatment.
Administration of MAM to naive rats, severely decreased the
generation of neurons (BrdUþ /NeuNþ cells, t8¼ 6.024;
P¼ 0.0003) and astrocytes (BrdUþ /GFAPþ cells,
t8¼ 2.889; P¼ 0.020) (Figures 1a and b) and induced
sustained deficits in hippocampal proliferation (Ki-67þ cells,
t8¼ 8.229; Po0.0001) (Figure 1c). As all neurons had
matured 4 weeks after BrdU injections, we did not find
DCXþ /BrdUþ cells. Treatment with the antimitotic drug
MAM produced increases in two surrogate measures of
depressive-like behavior (reduced sucrose preference, a
reflection of an anhedonic state, t18¼ 1.941; P¼ 0.034,
Figure 1d; increased immobility in the FST, t18¼ 3,889;
P¼ 0.001, Figure 1e). MAM administration also elicited signs
of increased anxiety, as measured in the EPM (t18¼ 4.069;
P¼ 0.0007, Figure 1f) and in the NSF (t18¼ 4.324; P¼
0.0004, Figure 1g and Supplementary Figure S1), an inter-
esting finding in light of the fact that a sizeable subpopulation
of depressed human subjects exhibit hyperanxiety. In addi-
tion, MAM treatment was associated with impaired spatial
working memory (F1,22¼ 5.726; P¼ 0.026, Figure 1h and
Supplementary Figure S2) and behavioral flexibility (t18¼ 4.158;
P¼ 0.0006, Figure 1i). Interestingly, new neurons (BrdUþ
neurons), that escaped mitotic blockade, were found to have
markedly reduced spine densities (t28¼ 6.412; Po0.0001,
Figure 1j) and altered spine morphology (Supplementary
Figure S7), as compared with neurons that had matured
before the experimental manipulations (Figure 1j).
Hippocampal neurogenesis and gliogenesis are funda-
mental for sustained spontaneous and pharmacological
recovery from depressive-like behavior. The importance
of active neurogenesis in the precipitation of depressive-like
behavior in animals exposed to uCMS, a validated animal
model of depression,15,20 was examined next. While most
studies only report on immediate, possibly transient, recov-
ery from stress, we here assessed ‘extended recovery’ by
evaluating the display of depressive-like behavior 4 weeks
after the cessation of stress (Figure 2a). In these experi-
ments, MAM was administered during the last 2 weeks of AD
treatment, allowing the examination of whether uninterrupted
neurogenesis is necessary for long-term—spontaneous and
AD treatment-associated—recovery from stress-induced
depressive-like behavior. Like MAM, stress attenuated
hippocampal neurogenesis and gliogenesis (F6,28¼ 17.35,
Po0.0001, post-hoc Po0.001 for neurons; F6,28¼ 6.079;
P¼ 0.0004, post-hoc Po0.01 for glia; Figures 3a–d) and
elicited signs of anhedonia in an AD-reversible manner.
However, the AD actions occurred independently of ongoing
neuroproliferation (Figures 2b and c). Animals exposed to
uCMS only showed partial spontaneous recovery, as
measured by the sucrose consumption test, but such
behavioral recovery was absent in animals exposed to
uCMS and MAM (F6,63¼ 4.005; P¼ 0.0019, post-hoc
Po0.001, Figures 2b and c). The latter animals showed
significantly reduced levels of neurogenesis (F6,28¼ 26.80;
Po0.0001, post-hoc Po0.001, Figure 3b) and proliferation
(F6,28¼ 26.80; Po0.0001, post-hoc Po0.001; Figures 3e
and f) for up to 4 weeks after cessation of uCMS and MAM
treatment. Strikingly, recovery during AD treatment was
insensitive to the arrest of neurogenesis (Figures 2b and c).
When tested in the forced swimming test (a test which
measures reversal of learned helplessness within 24 h of AD
treatment21), rats showed spontaneous and pharmacologi-
cally-induced recovery from the effects of uCMS, indepen-
dently of ongoing neurogenesis (Figure 2d).
Anxiety traits frequently form part of the symptomatic profile
of depressed patients and animal models of depression.8,22–24
Ablation of hippocampal neurogenesis was here found to
prevent the spontaneous reinstatement of baseline emotional
states in animals previously exposed to uCMS; this
was evident in two tests of anxiety-like behavior, EPM
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(F6–63¼ 4.122; P¼ 0.0015, post-hoc Po0.01, Figure 2e) and
NSF (F6–63¼ 8.932; Po0.0001, post-hoc Po0.001,
Figure 2f). Both imipramine and fluoxetine normalized the
anxious phenotype induced by uCMS, but whereas the
therapeutic effects of fluoxetine were compromised by MAM
administration (t18¼ 1.739; P¼ 0.0495 in the EPM, Figure 2e;
and t18¼ 1.893; P¼ 0.0373 in the NSF, Figure 2f), those of
imipramine were not (P40.05 in both tests, Figures 2e and f).
Complaints of cognitive impairment are common among
depressed subjects. Stress is known to dysregulate a
number of cognitive functions that depend on the structural
integrity of the hippocampus, prefrontal cortex and reciprocal
connections between these two regions. Here, we show that
arrest of neurogenesis prevents spontaneous improvements
in spatial behavioral flexibility (F6–63¼ 2.309, Po0.0445,
post-hoc Po0.05, Figure 2g) and spatial working memory
Figure 1 Neurogenesis arrest induces long-term emotional and cognitive changes typical of depression. (a) Neurogenesis was arrested by methylazoxymethanol (MAM)
administration and the effects on behavior were assessed after 4 weeks. MAM treatment decreased the number of BrdU-positive cells in the hippocampal dentate gyrus (b),
that underwent neuronal (BrdU/NeuN) and astroglial (BrdU/GFAP) differentiation. (c) Deficits in proliferation were sustained 4 weeks after MAM treatment cessation.
Behavioral phenotype was evaluated using a battery of tests to assess distinct behavioral domains affected in depression. (d, e) Long-term mood impairments were observed
in the sucrose consumption test (SCT) (d), and in the forced swimming test (FST) (e) 4 weeks after MAM treatment. (f, g) Increased anxiety-like behavior was detected in the
elevated plus maze test (EPM) (f) and in the novelty-suppressed feeding test paradigm (NSF) (g) in animals previously treated with MAM. (g, h) Cognitive performance was
also affected 4 weeks after neurogenesis arrest, as both (h) working memory and (i) behavioral flexibility were impaired 4 weeks after MAM administration. MAM treatment did
not affect the dendritic length of neither preexistent or newly born granule neurons (j), but there was a decrease in spine density in the dendrites of newly born neurons after
MAM exposure. Error bars denote s.e.m. *Po0.05, **Po0.01, ***Po0.001; n¼ 10–12 per group.
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(F2–33¼ 3.768, P¼ 0.034, post-hoc Po0.05, Figure 2h) for up
to 4 weeks after cessation of the uCMS paradigm. Impair-
ments induced by uCMS were reversed by both imipramine
and fluoxetine (post-hoc Po0.05 in both tests; Figures 2g
and i), but interestingly, whereas fluoxetine failed to restore
working memory when it was coadministered with MAM, the
cognition-improving efficacy of imipramine did not depend on
active neurogenesis (F3–31¼ 3.081, P¼ 0.041 post-hoc
Po0.05, Figure 2j). Imipramine treatment elicited a strong
pro-gliogenic effect (F6–28¼ 6.079; P¼ 0.0004, post-hoc
Po0.01, Figure 3b), as compared with fluoxetine which was
more effective at promoting differentiation of newly born cells
into neurons rather than astroglia (F6–28¼ 17.35, Po0.0001,
post-hoc Po0.001). Consistently, blockade of neurogenesis
with MAM did not interfere with the ability of imipramine to
improve working memory (post-hoc P40.05, Figure 2j).
Figure 2 Neurogenesis arrest prevents long-term recovery from depression. (a) The relevance of neurogenesis for long-term recovery from depression was evaluated in
animals exposed to an unpredictable chronic mild stress (uCMS) protocol 4 weeks before behavioral assessment. (b, c) Stress exposure triggers anhedonic behavior, that was
reverted by fluoxetine and imipramine. Neurogenesis arrest with mehylazoxymethanol (MAM) in stressed animals precluded recovery from anhedonic signs in the sucrose
consumption test (SCT). (d) Learned helplessness behavior, assessed in the forced swimming test (FST), was normalized after 4 weeks of spontaneous or antidepressant-
induced recovery from stress. (e, f) The long-term recovery from anxiety-like behavior was prevented by neurogenesis arrest; fluoxetine anxiolytic effects were attenuated by
MAM administration, while imipramine action remained unaffected. (g–j) Neurogenesis arrest prevented the recovery form cognitive deficits in (g) behavioral flexibility and in
(h) working memory of animals exposed to uCMS; (i, j) the therapeutical action of fluoxetine on working memory was suppressed by MAM administration, while imipramine
effect was maintained after neurogenesis arrest. Error bars denote s.e.m. *Denotes the effect of MAM;}Denotes the effect of uCMS; #Denotes the antidepressants effect, by
comparison of the antidepressants-treated animals with uCMS animals. *,}, #Po0.05, **,}}, ##Po0.01, ***,}}}, ###Po0.001; n¼ 10–12 per group. EPM, elevated plus
maze test; NSF, novelty-suppressed feeding test paradigm.
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uCMS induces sustained neuromorphological changes
in newly born hippocampal neurons. Mood, anxiety and
cognitive performance are regulated by dynamic alterations
in synaptic and dentritic structure and function.8,25,26 The
present study shows that the neuromorphological changes
that we previously observed immediately after uCMS
Figure 3 Pro-neurogenic and pro-gliogenic actions of the antidepressants fluoxetine and imipramine are associated with emotional and cognitive long-term recovery from
depression. (a, b) Micrographs depict examples of (a) BrdU/NeuN double-labeled neurons and (b) BrdU/GFAP double-labeled glial cells in the hippocampal dentate-gyrus (DG) of
control animals. (c, d) Graphs show the density of (c) total BrdU labeled cells and of (d) BrdU/NeuN, to evaluate neurogenesis, and BrdU/GFAP double-labeled cells, to evaluate
gliogenesis, in the hippocampal DG. Unpredictable chronic mild stress (uCMS) animals, with or without methylazoxymethanol (MAM) treatment, have significantly lower levels of
neurogenesis and gliogenesis when compared with control animals. Fluoxetine and imipramine treatment leads to a recovery in the levels of neurogenesis and gliogenesis,
respectively. (e) Proliferation analyses, assessed at the end of the 4-weeks recovery period, by Ki67 staining, showed that uCMS and antidepressant-treated animals have similar
proliferation levels to control animals. The uCMS effect on proliferation was prevented by neurogenesis arrest with MAM administration. (f) Micrograph depicts Ki67 labeled cells in
the hippocampal DG of a control animal. *Denotes the effect of MAM;}Denotes the effect of uCMS; #Denotes the antidepressants effect, by comparison of the antidepressants-
treated animals with uCMS animals. *,}, #Po0.05, **,}},##Po0.01, ***,}}}, ###Po0.001; n¼ 5 per group. DAPI, 4’,6-diamidino-2-phenylindole.
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exposure8 are fully reversed after a 4-week period of
recovery (Figure 4a). In fact, no differences were observed
in the dendritic morphology and spine density of mature
dentate gyrus neurons between controls and animals
previously submitted to uCMS (Figure 4a). However, using
the novel Immuno-Golgi method to distinguish between
newly born and preexisting neurons,19 we observed that
uCMS affects neither dendritic extension (Figures 4b and c)
nor overall spine density (Figure 4d) in newborn neurons;
rather, our analysis revealed that new cells generated during
spontaneous and AD-induced recovery from uCMS have an
unusually greater density of thin spines (F4–70¼ 5.103,
Figure 4 Exposure to unpredictable chronic mild stress (uCMS) causes long-term neuromorphological alterations in newborn granule neurons. (a) Structural changes in
the dendritic arborization of preexisting granule neurons in the hippocampal dentate gyrus (DG), analyzed with the Golgi-Cox impregnation method, induced by uCMS
exposure are reverted at long-term (4 weeks after uCMS exposure). (b–d) uCMS exposure does not have long-term impact on the dendritic arborization (b, c), neither in the
global spine density of newborn neurons in the hippocampal DG (d), analyzed with the Immuno-Golgi method (co-labeling of BrdU and Golgi-Cox staining). (e, f) Newborn
granule neurons of rats exposed to uCMS 4 weeks before, present increased percentage of thin spines; these alterations are attenuated in the animal groups treated with both
antidepressants (e, f). }Denotes the effect of uCMS; }Po0.05; n¼ 10–15 per group.
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P¼ 0.0011, post-hoc Po0.05; Figures 4e and f). As thin
spines are a common feature in conditions of reduced
cognitive function,27,28 these findings indicate that uCMS
leaves persistent morphological and behavioral scars. Inter-
estingly MAM treatment mimicked sustained spines altera-
tions in BrdUþ neurons produced by uCMS exposure, which
were reversed by ADs coadministration (Supplementary
Figure S7).
Discussion
Overall, the present results show that the appropriate
incorporation of newly born hippocampal cells in preexisting
neural networks is essential for spontaneous recovery from
depression-associated emotional and cognitive impairments
in rats; moreover, these processes are important for long-term
maintenance of the behavioral homeostasis achieved through
the use of ADs.
Indeed, hippocampal cell proliferation arrest by MAM on
untreated animals caused a 70% reduction on neurogenesis
and gliogenesis, similarly to the anti-proliferative effects
produced by uCMSexposure, which were causally associated
with long-lasting emotional and cognitive disabilities. Remark-
ably, MAM treatment in naive animals produced behavioral
deficits resembling those manifested after chronic exposure
to stress. In this regard, it is important to note that such
emotional and cognitive impairments emerged only 4 weeks
after cessation of MAM treatment and were not manifested
shortly after neurogenesis ablation, as we have showed
previously.8 Considering the late manifestation of these
behavioral disabilities, it is inferable that continuous prolifera-
tion and complete circuitry integration of new neurons and
glial cells, a process that takes 4–6 weeks in rodents, is
necessary for the maintenance of emotional and cognitive
homeostasis.
In line with the idea that continuous hippocampal cell
proliferation is relevant for the spectrum of depressive
symptoms, is the present observation that the ability of ADs
to reverse emotional and cognitive impairments relies on their
potential to restore hippocampal neuro- and glio-genesis. An
interesting finding is that different classes of ADs have distinct
impact on newborn cells-fate, that are reflected in different
behavioral effects. As data suggests, noradrenaline reuptake
inhibitors (imipramine) can ameliorate anxiety and cognitive
deficits induced by stress independently of ongoing neuro-
genesis, whereas the anxiolytic and pro-cognitive efficacy of
serotonin reuptake inhibitors (fluoxetine) require uninter-
rupted neurogenic processes.
These findings are consistent with earlier demonstrations of
the essential role of neurogenesis in the regulation of anxiety
behavior8,9,24,29 and cognitive function30,31 although the distinct
contributions of serotoninergic and noradrenergic pathways to
this regulation have not been previously reported. In light of
recent data suggesting that astrocytic dysfunction and glial
pathology have an important role in the regulation of emotional
and cognitive behavior,12,32,33 our observation that imipramine
treatment promotes the generation and differentiation of new
hippocampal cells into astrocytes may explain its strong ability
to counteract MAM treatment; this is consistent with the fact
that, norepinephrine, in contrast to serotonin, can directly
activate the resident pool of progenitor cells and stimulate
neurogenic, as well as gliogenic processes.34
In addition, the present results indicate that reestablishment
of synaptic connections in hippocampal networks is a likely
prerequisite for the spontaneous and pharmacological
restoration of normal emotional and cognitive states. Studies
demonstrating the fast behavioral actions of ketamine, an
NMDA receptor antagonist, support this view.35 However, we
also reveal, for the first time, the occurrence of persistent
alterations in spine morphology in neurons that escaped the
stress- or MAM-induced hippocampal arrest that might be of
relevance for future exposures to stressful conditions. Overall,
our findings suggest that slower neuroplastic changes,
involving neurogenesis and complex dynamic remodeling of
neuro-glial networks, appear to have an important role in
determining the extent of recovery from, and eventual relapse
of, depressive symptoms.
In summary, this work suggests that cytogenic alterations
are relevant but cannot account for the entire behavioral
phenotypic recover after the remission from depressive-like
behavior, as some behavioral alterations do not correlate with
variations in neuro- and glio-genesis. Thus, most likely the
incorporation of newly born cells into preexistent circuits
impact, in combination with complementary neuroplastic and
neuroendocrine alterations, on cortico-limbic circuitries
involved in the remission from depressive symptomatology.
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